Medtronic

MEDTRONIC RECEIVES HEALTH CANADA LICENCE FOR FIRST OF ITS KIND RADIAL ACCESS CATHETER SYSTEM TO HELP TREAT NEUROVASCULAR CONDITIONS

Device Specifically Designed for Neuro Interventions Using Radial Artery Pathway in the Wrist

BRAMPTON, Ontario – July 15, 2021 – Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE:MDT) – the global leader in medical technology – has received a licence from Health Canada for Rist™ 079 Radial Access Guide Catheter and Rist™ Radial Access Selective Catheter, adding the first-of-its-kind radial access catheter system to the Medtronic neurovascular portfolio, enhancing the ability to serve patients requiring interventional neurovascular therapy.

The Rist 079 Radial Access Guide Catheter is indicated for the introduction of interventional devices into the peripheral, coronary, and neurovasculature. It is the first catheter designed and licensed specifically to navigate the radial artery pathway in the wrist for neurointerventions. When compared to the traditional femoral approach, transradial access (TRA) has been associated with significantly reduced access site complications when accessing the neurovasculature.1

“Cardiac interventions have been treated through TRA techniques for many years due to lower access complication rates,” said Dr. Sachin Pandey, radiologist from London Health Sciences Centre. “That’s why as an interventional neuroradiologist, I am pleased to finally have a device dedicated to this type of approach in the neurovascular field.”

“The Rist radial access portfolio is a pivotal addition to our family of neurovascular products,” said Donna Wong, commercial leader of the Neurovascular business at Medtronic Canada. “Medtronic is the first company to create a dedicated device that helps reduce issues around this challenging access site, and we look forward to collaborating with the Canadian neuro-interventionalist community towards improving patient outcomes.”

About Medtronic Canada ULC

Proud to serve Canadian healthcare for over 50 years, Medtronic Canada ULC (www.medtronic.ca), is a subsidiary of Medtronic plc, the world’s largest medical technology, services, and solutions companies – alleviating pain, restoring health, and extending life for millions of people around the world. Serving physicians, hospitals, and patients across the country, Medtronic Canada ULC is headquartered in Brampton, Ontario, with regional offices in Montreal and Vancouver. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-

1 Li, Y., et al., Lower complication rates associated with transradial versus transfemoral flow diverting stent placement. J Neurointerv Surg, 2021. 13(1): p. 91-95.

Carmela Reyes

Ryan Weispfenning